| Literature DB >> 36247762 |
Laetitia Peultier-Celli1,2, Roland Jaussaud1,3, Pierre Kaminsky1,3, Joëlle Deibener-Kaminsky3, François Feillet4, Philippe Perrin1,2,5.
Abstract
Background: Fabry disease (FD) is a rare inherited lysosomal storage disorder caused by the deficiency of the enzyme alpha-galactosidase A. This deficiency leads to an accumulation of glycosphingolipids leading to progressive and multisystemic disease, including renal, cardiac, and neurological damages. FD may also have neuro-otological and visual impairments, which can generate postural control alterations, inner ear, and vision being involved in this function. This study aimed to evaluate the impact of FD on postural control.Entities:
Keywords: Fabry disease; cochleo-vestibular disorders; postural control; posturography; rehabilitation
Year: 2022 PMID: 36247762 PMCID: PMC9564708 DOI: 10.3389/fneur.2022.856946
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Figure 1The six conditions of the SOT (EquiTest, NeuroCom International Inc., Clackamas, OR, USA). Conditions 1–3 were performed on a fixed platform with eyes open, eyes closed and vision sway-referenced. Conditions 4–6 were performed on a sway-referenced platform (somatosensory input inaccurate) with eyes open, eyes closed and vision sway-referenced (visual input inaccurate).
Sensory organization test.
|
|
|
|
|---|---|---|
| Condition 1 (C1) | Eyes open, fixed support | - |
| Condition 2 (C2) | Eyes closed, fixed support | Vision absent |
| Condition 3 (C3) | SR surround, fixed support | Altered vision |
| Condition 4 (C4) | Eyes open, SR support | Altered proprioception |
| Condition 5 (C5) | Eyes closed, SR support | Vision absent, altered proprioception |
| Condition 6 (C6) | SR surround, SR support | Altered vision and proprioception |
|
|
| |
| Somatosensory (RSOM) | C2/C1 | Question: does sway increase when visual cues are removed? |
| Visual (RVIS) | C4/C1 | Question: does sway increase when somatosensory cues inaccurate? |
| Vestibular (RVEST) | C5/C1 | Question: does sway increase when visual cues are removed and somatosensory cues are inaccurate? |
Determination of the six conditions and significance of sensory ratios (17–19).
The composite equilibrium score (CES) was calculated by adding the average scores from conditions C1 + C2 + 3 x C3 + 3 x C4+ 3 x C5+ 3 x C6 / 14.
SR, sway-referenced.
Figure 2Sensory organization test. On the left: normal values of the Composite score (82) and of RSOM, RVIS, RVEST. Strategy analysis: ankle dominant, Center of gravity (COG) alignment: normal. On the right: Fabry disease patient (patient No 14): low Composite score (51), low values of RSOM and RVEST. Strategy: ankle and hip dominant strategies and falls according to the condition. Center of gravity shifted to the backward position.
Posturographic and vestibular results in the Fabry disease patient group.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1 | 77 | 0.71 | 0.79 | 0.99 | RVIS slightly | - | |
| 2 | 78 | 0.62 | 0.83 | 1.01 | Normal | - | |
| 3 |
| 81 | 0.70 | 0.93 | 0.97 | Normal | Nothing to notice |
| 4 |
| 74 | 0.65 | 0.70 | 1.00 | RVIS | Interpretation disturbed by strabismus |
| 5 | 82 | 0.68 | 0.89 | 0.99 | Normal | - | |
| 6 | 85 | 0.83 | 0.98 | 0.96 | Normal | - | |
| 7 |
| 83 | 0.72 | 0.95 | 0.98 | Normal | Nothing to notice (orthostatic hypotension) |
| 8 | 51 | 0.00 | 0.68 | 0.86 | RVEST | Left vestibular areflexia | |
| 9 | 72 | 0.59 | 0.84 | 0.99 | Normal | - | |
| 10 | 76 | 0.65 | 0.77 | 0.96 | RVIS | - | |
| 11 |
| 66 | 0.00 | 0.88 | 0.85 | CES | Bilateral vestibular areflexia |
| 12 |
| 49 | 0.00 | 0.77 | 0.85 | RVEST | Left vestibular areflexia |
| 13 |
| 67 | 0.52 | 0.75 | 0.94 | CES | Interpretation disturbed by epilepsy treatment and vergence deficit |
| 14 |
| 51 | 0.10 | 0.73 | 0.78 | CES | Bilateral vestibular hyporeflexia |
| 15 |
| 72 | 0.58 | 0.79 | 0.96 | RVEST | Vestibular central pathology Saccadic ocular pursuit |
| 16 | 83 | 0.72 | 0.87 | 0.98 | Normal | - |
|
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Family 1 | 1 | 15–19 | 2, 3, 4 | Slight | + | Myopia | Acroparesthesia | Bilateral end-point nystagmus | ||||
| 2 | 20–24 | 1, 3, 4 | Slight | Astigmatism | Acroparesthesia | |||||||
| 3 | 25–29 | 1, 2, 4 | Normal | + | CV, astigmatism, hypermetropia | Acroparesthesia | Bilateral end-point nystagmus | |||||
| 4 | 45–49 | 1, 2, 3 | Moderate | + orthostatic hypotension | Astigmatism, myopia | Cephalalgia (visual) | Vergence deficit | |||||
| Family 2 | 5 | 25–29 | Slight | Acroparesthesia | Vergence deficit | |||||||
| 6 | 30–34 | 7 | Normal | Hypermetropia | Acroparesthesia | MRI periventricular hypersignals | Nephrotic syndrom | |||||
| 7 | 60–64 | 6 | Moderate | + | + orthostatic hypotension | Bilateral end-point nystagmus | Severe | |||||
| Family 3 | 8 | 10–14 | 9, 10, 11, 12 | Slight | Instability | |||||||
| 9 | 5–9 | 8, 10, 11, 12 | Normal | |||||||||
| 10 | 35–39 | 8, 9, 11, 12 | Unilateral sudden hearing loss | + | Acroparesthesia | MRI periventricular hypersignals | Vergence deficit, saccadic ocular pursuit | HCM | ||||
| 11 | 35–39 | 8, 9, 10, 12 | Slight | + | + | Acroparesthesia | Pituitary adenoma | Instability | ||||
| 12 | 40–44 | 8, 9, 10, 11 | Slight | + | + orthostatic hypotension | Acroparesthesia | Instability | Mild | ||||
| Family 4 | 13 | 35–39 | 14 | Slight | + (VVS, epilepsia) | Astigmatism, myopia | MRI periventricular hypersignals | Bilateral end-point nystagmus, vergence deficit | Instability | |||
| 14 | 40–44 | 13 | Slight | + | Migraine, darkness phobia | Instability | ||||||
| Family 5 | 15 | 50–54 | Moderate | + | + | CV, astigmatism, hypermetropia | Acroparesthesia | saccadic ocular pursuit | Moderate | |||
| Family 6 | 16 | 40–44 | Moderate | CV, astigmatism, hypermetropia | MRI periventricular hypersignals | ESRD | ||||||
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| 1 | 1 | 15–19 | IVS4-2 A>T | c.640-2A>T | − | AA | 3 | |
| 2 | 20–24 | IVS4-2 A>T | c.640-2A>T | − | AA | 3 | ||
| 3 | 25–29 | IVS4-2 A>T | c.640-2A>T | − | AA | 0.5 | ||
| 4 | 45–49 | IVS4-2 A>T | c.640-2A>T | − | - | 0 | Anti AHT | |
| 2 | 5 | 25–29 | p.A143T | c.427G > A | + | - | 0 | |
| 6 | 30–34 | p.A143T | c.427G>A | + | AB | 3 | ||
| 7 | 60–65 | p.A143T | c.427G>A | + | AB | 0.5 | Anti vertiginous | |
| 3 | 8 | 10–14 | p.M42R | c.125 T>G | + | - | 0 | |
| 9 | 5–9 | p.M42R | c.125 T>G | + | - | 0 | ||
| 10 | 35–39 | p.M42R | c.125 T>G | + | AA | 1 | Anti AHT | |
| 11 | 35–39 | p.M42R | c.125 T>G | + | - | 0 | Vestibular Rehabilitation, anti vertiginous | |
| 12 | 40–44 | p.M42R | c.125 T>G | + | AA | 1 | ||
| 4 | 13 | 35–39 | p.P205S | c.613 C>T | + | - | 0 | Antiepileptic |
| 14 | 40–44 | p.P205S | c.613 C>T | + | - | 0 | Balance Rehabilitation | |
| 5 | 15 | 50–54 | del 50 pb Ex7 | del 50 pb Ex7 | − | AA | 5 | |
| 6 | 16 | 40–44 | - | − | - | AA | 4 | |
Anti AHT, anti-arterial hypertension; HCM, hypertrophic cardiomyopathy; CV, cornea verticillata; ESRD, End-stage renal disease; VVS, vasovagal syndrome; ERT, Enzyme replacement therapy; AA, AB, agalsidase alfa, beta; MRI, Magnetic Resonance imaging.